A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of mani...
This historical record does not confirm current site availability.
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Finland · Hungary and 1 more location
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This is historical registry information. What is the current study status and protocol?
Things to check before joining
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 430
- Sponsor
- Novartis Farmacéutica, S.A.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Finland, Hungary, Spain
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2004-000113-18
- Official title
Show the full official title
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of mani...
Recruitment & locations
Finland · Hungary · Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Novartis Farmacéutica, S.A.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
